A patient with Poland syndrome presents with acute pericarditis, underscoring diagnostic hurdles in chest pain due to ...

Carly Pearce shared a health update with fans Thursday, revealing she has developed a heart condition called pericarditis. In a video posted to her Instagram, Pearce, 34, said: "Hey, y'all. I have ...

Country music singer and songwriter Carly Pearce has shared details about an ongoing health condition. The 34-year-old said she will continue performing, although those performances might look a bit ...

Pericarditis is an immune condition, not, strictly speaking, a cardiologic condition. Wax had been physically active ...

Myocarditis and pericarditis are conditions that involve heart inflammation. Myocarditis affects the heart muscle itself, while pericarditis impacts the pericardium — the layer of tissue that ...

Recurrence is a serious complication of acute pericarditis. Recurrent pericarditis is a term used when a pericarditis patient relapses after discontinuation of treatment. It can also be described as a ...

Sequence variants that protect against pericarditis have been discovered at a genomic locus encoding interleukin-1 immune cytokines. A newly approved drug treatment for pericarditis inhibits these ...

Please provide your email address to receive an email when new articles are posted on . In patients with lupus, those taking prednisone or demonstrating active disease and a more recent initial ...

Rilonacept, an interleukin (IL)-1 inhibitor, produces rapid resolution of recurrent pericarditis and fewer recurrent pericarditis episodes among patients who initially respond to drug therapy, as ...

Although allogeneic hematopoietic stem cell transplantation (HSCT) can be curative for various hematological disorders, it continues to be associated with a significant incidence of treatment-related ...

- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis -- Commercial launch expected in April 2021 -- Kiniksa launches Kiniksa One Connect™ patient support program -- ...